We are live on
!
Find out more
TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
1-Year Est. Return
58.09%
This Fund
S&P 500
This Quarter
Est. Return
+18.34%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$261M
AUM Growth
-$25M
(-8.7%)
Cap. Flow
-$67.9M
Cap. Flow
% of AUM
-26.04%
Top 10 Holdings %
Top 10 Hldgs %
67.6%
Holding
31
New
10
Increased
1
Reduced
16
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Steris
STE
|
+$13M |
| 2 |
HOLX
Hologic
HOLX
|
+$11.6M |
| 3 |
Pacira BioSciences
PCRX
|
+$9.34M |
| 4 |
NVRO
NEVRO CORP.
NVRO
|
+$5.58M |
| 5 |
ARIA
Ariad Pharmaceuticals Inc
ARIA
|
+$3.75M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PDCO
Patterson Companies, Inc.
PDCO
|
+$25.1M |
| 2 |
Quest Diagnostics
DGX
|
+$13.8M |
| 3 |
Alkermes
ALKS
|
+$10.4M |
| 4 |
ELGX
Endologix Inc
ELGX
|
+$10.2M |
| 5 |
NXTM
NxStage Medical Inc.
NXTM
|
+$8.92M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 75.74% |
| 2 | Technology | 7.03% |
| 3 | Communication Services | 0.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ELGX
1
DELISTED
Endologix Inc
ELGX
| $36.3M | 13.91% |
291,000
-89,000
| -23% | -$10.2M |
|
|
NXTM
2
DELISTED
NxStage Medical Inc.
NXTM
| $26M | 9.98% |
1,200,000
-500,000
| -29% | -$8.92M |
|
|
IMPR
3
DELISTED
IMPRIVATA, INC COM
IMPR
| $18.3M | 7.03% |
1,309,800
-400,200
| -23% | -$5.25M |
|
|
ARIA
4
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $15.5M | 5.95% |
2,100,000
+500,000
| +31% | +$3.75M |
|
|
5
Quest Diagnostics
DGX
$25.1B
| $14.9M | 5.73% |
183,457
-181,543
| -50% | -$13.8M |
|
6
Medtronic
MDT
$107B
| $14.7M | 5.62% |
169,000
-81,000
| -32% | -$6.55M |
|
|
SPNC
7
DELISTED
Spectranetics Corp
SPNC
| $13.4M | 5.13% |
714,200
-385,800
| -35% | -$6.79M |
|
|
MDRX
8
DELISTED
Veradigm Inc. Common Stock
MDRX
| $12.8M | 4.92% |
1,010,000
-640,000
| -39% | -$8.49M |
|
|
9
Steris
STE
$20.9B
| $12.7M | 4.88% |
+185,000
| New | +$13M |
|
|
HOLX
10
DELISTED
Hologic
HOLX
| $11.6M | 4.45% |
+335,000
| New | +$11.6M |
|
|
LMNX
11
DELISTED
Luminex Corp
LMNX
| $10.6M | 4.08% |
526,000
-224,000
| -30% | -$4.49M |
|
|
12
Alkermes
ALKS
$8.82B
| $10.1M | 3.86% |
233,000
-252,000
| -52% | -$10.4M |
|
13
Bio-Rad Laboratories Class A
BIO
$8.42B
| $10M | 3.84% |
70,000
-30,000
| -30% | -$4.28M |
|
14
Labcorp
LH
$24.3B
| $9.77M | 3.75% |
87,300
-46,560
| -35% | -$5.01M |
|
|
15
Pacira BioSciences
PCRX
$1.02B
| $6.41M | 2.46% |
+190,000
| New | +$9.34M |
|
|
NVRO
16
DELISTED
NEVRO CORP.
NVRO
| $6.06M | 2.33% |
+82,200
| New | +$5.58M |
|
17
DexCom
DXCM
$27.6B
| $5.16M | 1.98% |
260,000
-24,000
| -8% | -$409K |
|
18
AtriCure
ATRC
$1.77B
| $4.75M | 1.82% |
336,000
-189,000
| -36% | -$2.88M |
|
|
AMRN
19
Amarin Corp
AMRN
$284M
| $3.89M | 1.49% |
90,000
-65,000
| -42% | -$2.44M |
|
|
SGNT
20
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
| $3.88M | 1.49% |
+259,336
| New | +$3.33M |
|
|
CORI
21
DELISTED
Corium International, Inc.
CORI
| $3.73M | 1.43% |
1,075,000
-310,000
| -22% | -$1.26M |
|
|
PDCO
22
DELISTED
Patterson Companies, Inc.
PDCO
| $2.85M | 1.09% |
4,750
-545,250
| -99% | -$25.1M |
|
|
RLYP
23
DELISTED
RELYPSA INC COM
RLYP
| $1.75M | 0.67% |
+94,475
| New | +$1.66M |
|
|
STRM
24
DELISTED
Streamline Health Solutions
STRM
| $1.37M | 0.52% |
75,867
| – | – |
|
25
Collegium Pharmaceutical
COLL
$1.14B
| $1.13M | 0.43% |
+94,908
| New | +$1.57M |
|
Similar funds
SCM
LBC
ICM
LCMP
GIP
STC
GC
DU
Tamarack Advisers's Q2 2016 Portfolio in Review
As of Q2 2016, Tamarack Advisers held 31 positions worth $261M, down 8.7% from $286M the previous quarter. Its ten largest holdings account for 68% of the portfolio.
Tamarack Advisers withdrew a net $67.9M in Q2 2016, closing 3 positions and reducing 16 holdings. Its most notable exit was Intersect ENT, Inc, an estimated $4.28M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 80% a quarter earlier, followed by Technology and Communication Services.
Against the trend, Tamarack Advisers opened a new position in Steris worth $12.7M.
- Tamarack Advisers's largest Q2 2016 buy was Steris: 185,000 shares worth $12.7M.
- Tamarack Advisers added most to Ariad Pharmaceuticals Inc in Q2 2016, an estimated $3.75M increase.
- Tamarack Advisers's biggest Q2 2016 reduction was Patterson Companies, Inc., cutting an estimated $25.1M.
- Tamarack Advisers fully exited Intersect ENT, Inc in Q2 2016, selling an estimated $4.28M.
- Tamarack Advisers's ten largest holdings make up 68% of its $261M portfolio in Q2 2016.
- Tamarack Advisers opened 10 new positions and closed 3 in Q2 2016.
- Tamarack Advisers's portfolio value fell 8.7% quarter-over-quarter to $261M.
Based on Tamarack Advisers's 13F filing for Q2 2016, filed 15 Aug 2016.